Soon we’ll not be supporting this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

CASI Pharmaceuticals Inc (CASI) USD0.01

Sell:$1.22 Buy:$1.23 Change: $0.12 (8.89%)
Market closed |  Prices as at close on 21 September 2021 | Switch to live prices |
Sell:$1.22
Buy:$1.23
Change: $0.12 (8.89%)
Market closed |  Prices as at close on 21 September 2021 | Switch to live prices |
Sell:$1.22
Buy:$1.23
Change: $0.12 (8.89%)
Market closed |  Prices as at close on 21 September 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

CASI Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of therapeutics for cancer and other medical needs. It operates through the development of targeted therapeutics for the treatment of cancer segment. Its product pipeline includes internal development of its lead drug candidate, ENMD-2076; MARQIBO, ZEVALIN and EVOMELA, and early-stage candidates in preclinical development. Its ENMD-2076 is an orally active, Aurora A/angiogenic kinase inhibitor with a kinase selectivity profile and multiple mechanisms of action. Its Marqibo is a sphingomyelin/cholesterol liposome-encapsulated, formulation of vincristine sulfate. Its ZEVALIN (ibritumomab tiuxetan) injection for intravenous use is a CD20-directed radiotherapeutic antibody. Its EVOMELA is an intravenous formulation of melphalan being investigated by Spectrum in the multiple myeloma transplant setting. Its pipeline also includes 2ME2 (2-methoxyestradial).

Contact details

Address:
9620 Medical Center Dr Ste 300
ROCKVILLE
20850-3396
United States
Telephone:
+1 (240) 8642600
Website:
www.casipharmaceuticals.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
CASI
ISIN:
US14757U1097
Market cap:
$188.73 million
Shares in issue:
139.80 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Wei-Wu He
    Chairman of the Board, Chief Executive Officer
  • Wei Zhang
    President, President of CASI China
  • Alexander Zukiwski
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.